StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) company profile

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$42.99−1.22 (-2.76%)

Close on Nov 17, 2026Market cap $6.07BP/E –Yield –

About Arrowhead Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Arrowhead Pharmaceuticals develops RNA interference (RNAi) therapeutics designed to treat severe and intractable diseases by silencing disease-causing genes. The company utilizes its proprietary Targeted RNA Molecule (TRiM) platform to trigger targeted, catalytic gene knockdown across diverse tissue types beyond the liver, including adipose tissue, muscle, pulmonary tissue, and the central nervous system. Arrowhead's primary commercialized product is REDEMPLO (plozasiran), an FDA-approved medicine for adults with familial chylomicronemia syndrome, complemented by a clinical pipeline targeting cardiometabolic, pulmonary, renal, and neurodegenerative disorders. The company serves adult patients suffering from rare and high-prevalence genetic disorders directly and partners with major pharmaceutical companies through licensing and co-development collaborations.

Arrowhead maintains clinical and preclinical drug development programs worldwide, with 18 discovered drug candidates in clinical trials spanning Phase 1 to Phase 3. The company conducts late-stage multi-center clinical trials internationally, holds patent protections across dozens of countries, and is expanding its commercial footprint. The text does not disclose the specific location of the company's corporate headquarters.

Summary of the business section of Arrowhead Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Arrowhead Pharmaceuticals, Inc.
Founded
1989
Headquarters
Pasadena, CA
Address
177 E Colorado Blvd, Suite 700 91105
Phone
(626) 696-4702
Employees
711, Sep 30, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
September 30
Auditor
KPMG LLP, San Diego, California

Stock & identifiers

Ticker
ARWR
Former tickers
ARW until Feb 6, 2023
Exchange
Nasdaq
IPO date
Dec 16, 1993
Shares outstanding
141M, Jul 30, 2026
Public float
$1.40B, Mar 31, 2025
Filer category
Large accelerated filer
Stock splits
1-for-10 reverse, Nov 17, 2011; 1-for-65 reverse, Jan 15, 2004
SEC CIK
879407
CUSIP
04280A100
ISIN
US04280A1007
FIGI
BBG000BRVKH0
Share class FIGI
BBG001SGT8G5
LEI
549300O3CSB8T7OZ3D66
EIN
46-0408024

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Christopher Richard AnzaloneChief Executive Officer, Director3,798,510
Daniel Joseph ApelChief Financial Officer172,792
James C. HamiltonChief Medical Officer226,958
Patrick O'BrienCOO472,848
Kenneth Allen MyszkowskiChief Financial Officer465,433
Adeoye Y. OlukotunDirector31,600
Michael S. PerryDirector111,459
Matthew Gregory CohenDirector11,882
Hongbo LuDirector57,662
Mauro FerrariDirector69,053
William D. WaddillDirector56,563
Victoria VakienerDirector37,683
Douglas S. IngramDirector46,215
Douglas B. GivenDirector136,667

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$9.03M$42.60M$2.09M$80$146
FY2024$12.42M-$5.36M$3.50M$31$94
FY2023$9.92M-$2.17M$3.15M$62$49
FY2022$12.03M-$40.07M$4.13M$77$67
FY2021$24.70M$69.06M$3.32M$145$116

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsIncentive payOtherTotalvs. prior year
Christopher Anzalone
President and Chief Executive Officer
$981.05K–$6.81M$1.24M$2.52K$9.03M-27%
Daniel Apel
Chief Financial Officer
$232.21K$200.00K$1.29M$226.41K$9.29K$1.75M–
Patrick O’Brien
Chief Operating Officer
$653.94K–$1.98M$365.64K$31.62K$3.03M-23%
James Hamilton
Chief Medical Officer
$617.51K–$1.98M$354.63K$15.07K$2.97M-15%
Kenneth Myszkowski
Former Chief Financial Officer
$496.78K–$1.98M$155.78K$28.60K$2.66M-25%
Tracie Oliver
Former Chief Commercial Officer
$43.19K––––$43.19K-99%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of September 30, 2025, the Company employed 711 full-time employees based at four facilities in the United States, including Pasadena and San Diego, California, and Madison and Verona, Wisconsin.”

Corporate history

Events identified from SEC filings

DateEventDetails
Dec 5, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 6, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 23, 2017ListingRegistration of securities on an exchange (Form 8-A)
Apr 6, 2016Name changeName changed from ARROWHEAD RESEARCH CORP to Arrowhead Pharmaceuticals, Inc.
Mar 5, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 15, 2011Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 24, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 9, 2011Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 24, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 14, 2010Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 19, 2010Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 21, 2009Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 10, 2009Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 27, 2009Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 9, 2009Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 18, 2009Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 23, 2008Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 18, 2008Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 25, 2007Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 16, 2006Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 6, 2006Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 9, 2005Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 6, 2005Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 9, 2004Name changeName changed from INTERACTIVE GROUP INC to ARROWHEAD RESEARCH CORP
Dec 29, 2003Late filingNotification of late filing
Feb 13, 2003Late filingNotification of late filing
Dec 26, 2002Late filingNotification of late filing
Aug 13, 2002Late filingNotification of late filing
May 13, 2002Late filingNotification of late filing
Feb 13, 2002Name changeName changed from INTERACTIVE INC to INTERACTIVE GROUP INC

See a number that looks wrong?